Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.

2.

Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review.

Marchetti M, Carobbio A, Capitoni E, Barbui T.

Am J Hematol. 2018 May;93(5):698-703. doi: 10.1002/ajh.25049. Epub 2018 Feb 10.

PMID:
29377227
3.

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data.

Ghirardi A, Carobbio A, Masciulli A, Barbui T.

Blood Cancer J. 2018 Jan 16;8(1):5. doi: 10.1038/s41408-017-0038-3. No abstract available.

4.

Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit.

Buoro S, Manenti B, Seghezzi M, Dominoni P, Barbui T, Ghirardi A, Carobbio A, Marchesi G, Riva I, Nasi A, Ottomano C, Lippi G.

J Clin Pathol. 2018 Apr;71(4):330-335. doi: 10.1136/jclinpath-2017-204643. Epub 2017 Aug 20.

PMID:
28824010
5.

A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.

Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A, Ghirardi A, Tognoni G.

Am J Hematol. 2017 Nov;92(11):1131-1136. doi: 10.1002/ajh.24851. Epub 2017 Jul 29.

PMID:
28699191
6.

Robotic Transnasal Endoscopic Skull Base Surgery: Systematic Review of the Literature and Report of a Novel Prototype for a Hybrid System (Brescia Endoscope Assistant Robotic Holder).

Bolzoni Villaret A, Doglietto F, Carobbio A, Schreiber A, Panni C, Piantoni E, Guida G, Fontanella MM, Nicolai P, Cassinis R.

World Neurosurg. 2017 Sep;105:875-883. doi: 10.1016/j.wneu.2017.06.089. Epub 2017 Jun 20.

PMID:
28645603
7.

Echocardiographic outflow pump ramp test in centrifugal-flow left ventricular assist device.

Iacovoni A, Vittori C, Fontana A, Carobbio A, Fino C, D'Elia E, Terzi A, Senni M.

Int J Artif Organs. 2017 Apr 18:0. doi: 10.5301/ijao.5000573. [Epub ahead of print]

PMID:
28430303
8.

No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.

Barbui T, Carobbio A, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM.

Haematologica. 2017 Jun;102(6):e219-e221. doi: 10.3324/haematol.2017.165126. Epub 2017 Mar 2. No abstract available.

9.

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.

Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A.

J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.

10.

Diagnostic impact of the 2016 revised who criteria for polycythemia vera.

Barbui T, Thiele J, Gisslinger H, Carobbio A, Vannucchi AM, Tefferi A.

Am J Hematol. 2017 May;92(5):417-419. doi: 10.1002/ajh.24684. Epub 2017 Mar 4. No abstract available.

11.

ACE inhibitors and cytoreductive therapy in polycythemia vera.

Barbui T, Masciulli A, Ghirardi A, Carobbio A.

Blood. 2017 Mar 2;129(9):1226-1227. doi: 10.1182/blood-2016-11-752600. Epub 2016 Dec 27. No abstract available.

12.

Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial.

Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, Finetti M, Cumetti D, Carobbio A, Ruperto N, Marcolongo R, Lorini M, Rimini A, Valenti A, Erre GL, Sormani MP, Belli R, Gaita F, Martini A.

JAMA. 2016 Nov 8;316(18):1906-1912. doi: 10.1001/jama.2016.15826.

PMID:
27825009
13.

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.

De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Barbui T.

Blood Cancer J. 2016 Nov 4;6(11):e493. doi: 10.1038/bcj.2016.103.

14.

The effect of arterial hypertension on thrombosis in low-risk polycythemia vera.

Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A.

Am J Hematol. 2017 Jan;92(1):E5-E6. doi: 10.1002/ajh.24583. No abstract available.

15.

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.

De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Rossi E, Betti S, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola R, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Sant'Antonio E, Vannucchi AM, Barbui T.

Leukemia. 2016 Oct;30(10):2032-2038. doi: 10.1038/leu.2016.85. Epub 2016 Apr 26.

PMID:
27113812
16.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A.

Blood Cancer J. 2015 Nov 27;5:e369. doi: 10.1038/bcj.2015.94. No abstract available.

17.

The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.

Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M.

Ann Oncol. 2015 Sep;26(9):1980-7. doi: 10.1093/annonc/mdv255. Epub 2015 Jun 2.

PMID:
26037795
18.

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.

Barbui T, Vannucchi AM, Carobbio A, Thiele J, Rumi E, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Pieri L, Pardanani A, Passamonti F, Finazzi G, Tefferi A.

Am J Hematol. 2015 May;90(5):434-7. doi: 10.1002/ajh.23970. Epub 2015 Feb 27.

19.

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T.

Leukemia. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. Epub 2014 Dec 8. No abstract available.

PMID:
25482134
20.

The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.

Barbui T, Thiele J, Carobbio A, Vannucchi AM, Tefferi A.

Leukemia. 2015 Apr;29(4):992-3. doi: 10.1038/leu.2014.328. Epub 2014 Nov 26. No abstract available.

PMID:
25425199
21.

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A.

Blood. 2014 Nov 6;124(19):3021-3. doi: 10.1182/blood-2014-07-591610. No abstract available.

22.

Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.

Massi D, Simi L, Sensi E, Baroni G, Xue G, Scatena C, Caldarella A, Pinzani P, Fontanini G, Carobbio A, Urso C, Mandalà M.

Mod Pathol. 2015 Apr;28(4):487-97. doi: 10.1038/modpathol.2014.137. Epub 2014 Oct 24.

23.

Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.

Finazzi G, Carobbio A, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM, Cazzola M, Passamonti F, Rambaldi A, Barbui T.

Blood. 2014 Oct 16;124(16):2611-2. doi: 10.1182/blood-2014-08-596676. No abstract available.

24.

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.

Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Rulli E, Deaglio S, Mandalà M.

Ann Oncol. 2014 Dec;25(12):2433-42. doi: 10.1093/annonc/mdu452. Epub 2014 Sep 15.

PMID:
25223485
25.

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

Lussana F, Carobbio A, Randi ML, Elena C, Rumi E, Finazzi G, Bertozzi I, Pieri L, Ruggeri M, Palandri F, Polverelli N, Elli E, Tieghi A, Iurlo A, Ruella M, Cazzola M, Rambaldi A, Vannucchi AM, Barbui T.

Br J Haematol. 2014 Nov;167(4):541-6. doi: 10.1111/bjh.13080. Epub 2014 Aug 16.

PMID:
25130523
26.

Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.

Martinelli I, De Stefano V, Carobbio A, Randi ML, Santarossa C, Rambaldi A, Finazzi MC, Cervantes F, Arellano-Rodrigo E, Rupoli S, Canafoglia L, Tieghi A, Facchini L, Betti S, Vannucchi AM, Pieri L, Cacciola R, Cacciola E, Cortelezzi A, Iurlo A, Pogliani EM, Elli EM, Spadea A, Barbui T.

Am J Hematol. 2014 Nov;89(11):E200-5. doi: 10.1002/ajh.23809. Epub 2014 Jul 31.

27.

Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.

Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A.

Leukemia. 2014 Oct;28(10):2092-4. doi: 10.1038/leu.2014.175. Epub 2014 Jun 3. No abstract available.

PMID:
24888272
28.

Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI).

Rizzi M, Ravasio V, Carobbio A, Mattucci I, Crapis M, Stellini R, Pasticci MB, Chinello P, Falcone M, Grossi P, Barbaro F, Pan A, Viale P, Durante-Mangoni E; Investigators of the Italian Study on Endocarditis.

BMC Infect Dis. 2014 Apr 29;14:230. doi: 10.1186/1471-2334-14-230.

29.

Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.

Barbui T, Thiele J, Carobbio A, Guglielmelli P, Rambaldi A, Vannucchi AM, Tefferi A.

Am J Hematol. 2014 Jun;89(6):588-90. doi: 10.1002/ajh.23694. Epub 2014 Mar 3.

30.

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N.

Haematologica. 2014 May;99(5):916-21. doi: 10.3324/haematol.2013.094284. Epub 2014 Jan 3.

31.

Masked polycythemia vera diagnosed according to WHO and BCSH classification.

Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E, Luigia Randi M, Vannucchi AM, Gisslinger B, Müllauer L, Ruggeri M, Rambaldi A, Tefferi A.

Am J Hematol. 2014 Feb;89(2):199-202. doi: 10.1002/ajh.23617.

32.

Masked polycythemia vera (mPV): results of an international study.

Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, Luigia Randi M, Betozzi I, Vannucchi AM, Pieri L, Carrai V, Gisslinger B, Müllauer L, Ruggeri M, Rambaldi A, Tefferi A.

Am J Hematol. 2014 Jan;89(1):52-4. doi: 10.1002/ajh.23585. Epub 2013 Sep 19. Erratum in: Am J Hematol. 2018 May;93(5):E133.

33.

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.

Barbui T, Carobbio A, Finazzi G, Guglielmelli P, Salmoiraghi S, Rosti V, Rambaldi A, Vannucchi AM, Barosi G.

Leukemia. 2013 Oct;27(10):2084-6. doi: 10.1038/leu.2013.207. Epub 2013 Jul 5. No abstract available.

PMID:
23828261
34.

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T.

Leukemia. 2013 Sep;27(9):1874-81. doi: 10.1038/leu.2013.163. Epub 2013 Jun 6.

35.

Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.

Ruella M, Salmoiraghi S, Risso A, Carobbio A, Buttiglieri S, Spatola T, Sivera P, Ricca I, Barbui T, Tarella C, Rambaldi A.

Exp Hematol. 2013 Jul;41(7):627-34. doi: 10.1016/j.exphem.2013.03.007. Epub 2013 Mar 28.

PMID:
23542632
36.

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A.

Blood. 2012 Dec 20;120(26):5128-33; quiz 5252. doi: 10.1182/blood-2012-07-444067. Epub 2012 Oct 1.

37.

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A.

Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26.

38.

Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.

Barbui T, Thiele J, Carobbio A, Passamonti F, Rumi E, Randi ML, Bertozzi I, Vannucchi AM, Gisslinger H, Gisslinger B, Finazzi G, Ruggeri M, Rodeghiero F, Rambaldi A, Gangat N, Tefferi A.

Blood. 2012 Jul 19;120(3):569-71. doi: 10.1182/blood-2012-01-407981. Epub 2012 Jun 13.

39.

Full-right-full-left split liver transplantation: the retrospective analysis of an early multicenter experience including graft sharing.

Zambelli M, Andorno E, De Carlis L, Rossi G, Cillo U, De Feo T, Carobbio A, Giacomoni A, Bottino G, Colledan M.

Am J Transplant. 2012 Aug;12(8):2198-210. doi: 10.1111/j.1600-6143.2012.04071.x. Epub 2012 May 11.

40.

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients.

Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Müllauer L, Frantal S, Carobbio A, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Finazzi G, Gangat N, Tefferi A, Barbui T.

Am J Hematol. 2012 Jul;87(7):669-72. doi: 10.1002/ajh.23217. Epub 2012 May 10.

41.

Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients.

Rambaldi A, Bacigalupo A, Fanin R, Ciceri F, Bonifazi F, Falda M, Lambertenghi-Deliliers G, Benedetti F, Bruno B, Corradini P, Alessandrino PE, Iacopino P, Arcese W, Scimè R, Raimondi R, Sica S, Castagna L, Lamparelli T, Oneto R, Lombardini L, Pollichieni S, Algarotti A, Carobbio A, Sacchi N, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo, GITMO.

Leukemia. 2012 Aug;26(8):1779-85. doi: 10.1038/leu.2012.55. Epub 2012 Mar 1.

42.

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Pieri L, Rotunno G, Gisslinger H, Gisslinger B, Müllauer L, Finazzi G, Carobbio A, Gianatti A, Ruggeri M, Nichele I, D'Amore E, Rambaldi A, Tefferi A.

Blood. 2012 Mar 8;119(10):2239-41. doi: 10.1182/blood-2011-11-393819. Epub 2012 Jan 13.

43.

Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.

Carobbio A, Finazzi G, Thiele J, Kvasnicka HM, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Luigia Randi M, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T.

Am J Hematol. 2012 Feb;87(2):203-4. doi: 10.1002/ajh.22241. Epub 2012 Jan 11.

44.

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.

Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T.

Leukemia. 2012 Apr;26(4):716-9. doi: 10.1038/leu.2011.258. Epub 2011 Sep 16.

PMID:
21926959
45.

ASXL1 mutations in primary and secondary myelofibrosis.

Ricci C, Spinelli O, Salmoiraghi S, Finazzi G, Carobbio A, Rambaldi A.

Br J Haematol. 2012 Feb;156(3):404-7. doi: 10.1111/j.1365-2141.2011.08865.x. Epub 2011 Sep 19. No abstract available.

PMID:
21923651
46.

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A.

J Clin Oncol. 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298. Epub 2011 Jul 11.

PMID:
21747083
47.

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T.

Blood. 2011 Jun 2;117(22):5857-9. doi: 10.1182/blood-2011-02-339002. Epub 2011 Apr 13.

48.

Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.

Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A.

J Clin Oncol. 2011 Mar 1;29(7):814-24. doi: 10.1200/JCO.2010.28.9777. Epub 2010 Dec 28.

PMID:
21189387
49.

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A; AGIMM and IIC Investigators.

Haematologica. 2011 Feb;96(2):315-8. doi: 10.3324/haematol.2010.031070. Epub 2010 Dec 20.

50.

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.

Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S, Finazzi MC, Di Tollo S, D'Urzo C, Vannucchi AM, Barosi G, Barbui T.

Br J Haematol. 2010 Aug;150(4):446-55. doi: 10.1111/j.1365-2141.2010.08266.x. Epub 2010 Jun 15.

PMID:
20560970

Supplemental Content

Loading ...
Support Center